Repositioning Vericiguat after VICTOR: Towards a Risk- and Timing-Based Framework in Contemporary HFrEF

Clicks: 11
ID: 332328
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #39 of 49 articles by views in European Heart Journal - Cardiovascular Pharmacotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Vericiguat, an oral soluble guanylate cyclase stimulator, provides a mechanistically distinct approach to reducing residual risk in heart failure with reduced ejection fraction (HFrEF). The VICTORIA trial demonstrated a reduction in cardiovascular death or heart failure hospitalisation among patients with recent worsening heart failure, whereas vericiguat did not significantly reduce the primary endpoint in the subsequent VICTOR trial in a more stable HFrEF population. Nevertheless, the prespecified pooled analysis of VICTORIA and VICTOR showed a significant reduction in cardiovascular death or first heart failure hospitalisation across the combined HFrEF population, without significant heterogeneity between the trials. Together, these findings shift the focus from efficacy alone to clinical prioritisation according to baseline risk and timing, while recognising that validated treatment-selection criteria and an optimal timing strategy remain undefined. Contemporary observational studies have identified associations between blood pressure, disease severity, prior heart failure hospitalisation, and clinical or biomarker outcomes during vericiguat treatment; however, these characteristics have not been validated as predictors of vericiguat-specific treatment benefit. This review integrates evidence from VICTORIA, VICTOR, pooled analyses, and contemporary real-world studies and proposes a hypothesis-generating, risk- and timing-based framework for vericiguat use. Clinically meaningful worsening heart failure may represent a period of increased absolute risk in which consideration of vericiguat may be particularly relevant after clinical stabilisation, but neither an optimal therapeutic window nor a validated responder phenotype has been established. Prospective studies specifically evaluating treatment-by-risk and treatment-by-timing interactions are required to validate this framework.
Reference Key
openalex_W7221749750 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Teruhiko Imamura
Are you one of these authors? Claim your profile
Journal European Heart Journal - Cardiovascular Pharmacotherapy
Year 2026
DOI
10.1093/ehjcvp/pvag092
URL
https://doi.org/10.1093/ehjcvp/pvag092
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.